These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 19644623

  • 41. Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis.
    Uhlig T, Moe R, Reinsberg S, Kvien TK, Cieza A, Stucki G.
    Ann Rheum Dis; 2009 Jun; 68(6):879-84. PubMed ID: 18625628
    [Abstract] [Full Text] [Related]

  • 42. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.
    Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Griffin MR.
    Med Care; 2007 Oct; 45(10 Supl 2):S66-76. PubMed ID: 17909386
    [Abstract] [Full Text] [Related]

  • 43. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
    Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH.
    Arthritis Rheum; 2007 Aug 15; 57(6):928-34. PubMed ID: 17665462
    [Abstract] [Full Text] [Related]

  • 44. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I, Koó E, Seszták M, Gergely P.
    Z Rheumatol; 2003 Apr 15; 62(2):155-60. PubMed ID: 12721703
    [Abstract] [Full Text] [Related]

  • 45. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X, Nordström D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JM, Woolley JM, Wright N, Lawrence C, Appleton B.
    J Rheumatol; 2008 Aug 15; 35(8):1538-44. PubMed ID: 18634163
    [Abstract] [Full Text] [Related]

  • 46. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.
    van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W.
    J Rheumatol; 2009 Oct 15; 36(10):2164-70. PubMed ID: 19723906
    [Abstract] [Full Text] [Related]

  • 47. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D, Smolen JS.
    Rheumatology (Oxford); 2002 Dec 15; 41(12):1367-74. PubMed ID: 12468815
    [Abstract] [Full Text] [Related]

  • 48. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
    Söderlin MK, Lindroth Y, Jacobsson LT.
    Rheumatology (Oxford); 2007 Aug 15; 46(8):1355-8. PubMed ID: 17567634
    [Abstract] [Full Text] [Related]

  • 49. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.
    Arthritis Rheum; 2009 Aug 15; 60(8):2248-56. PubMed ID: 19644853
    [Abstract] [Full Text] [Related]

  • 50. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G, Barner JC, Rascati K, Richards K.
    Clin Ther; 2016 Mar 15; 38(3):646-54. PubMed ID: 26899313
    [Abstract] [Full Text] [Related]

  • 51. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996.
    Ward MM, Fries JF.
    J Rheumatol; 1998 Mar 15; 25(3):408-16. PubMed ID: 9517756
    [Abstract] [Full Text] [Related]

  • 52. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
    Rodriguez-Rodriguez L, Jover-Jover JA, Fontsere O, Peña-Blanco RC, León L, Fernández-Gutierrez B, Abásolo L.
    Scand J Rheumatol; 2013 Mar 15; 42(6):433-6. PubMed ID: 23742043
    [Abstract] [Full Text] [Related]

  • 53. Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice.
    Montag K, Gingold M, Boers A, Littlejohn G.
    Intern Med J; 2011 Jun 15; 41(6):450-5. PubMed ID: 20403067
    [Abstract] [Full Text] [Related]

  • 54. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug 15; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 55. Patterns of drug use in rheumatoid arthritis.
    Bérard A, Solomon DH, Avorn J.
    J Rheumatol; 2000 Jul 15; 27(7):1648-55. PubMed ID: 10914846
    [Abstract] [Full Text] [Related]

  • 56. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.
    Schipper LG, Fransen J, Barrera P, Van Riel PL.
    Rheumatology (Oxford); 2009 Jul 15; 48(7):828-33. PubMed ID: 19458163
    [Abstract] [Full Text] [Related]

  • 57. The use of conventional disease-modifying anti-rheumatic drugs in established RA.
    Jurgens MS, Jacobs JW, Bijlsma JW.
    Best Pract Res Clin Rheumatol; 2011 Aug 15; 25(4):523-33. PubMed ID: 22137922
    [Abstract] [Full Text] [Related]

  • 58. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine.
    Capell HA, Maiden N, Madhok R, Hampson R, Thomson EA.
    J Rheumatol; 1998 Oct 15; 25(10):1880-6. PubMed ID: 9779839
    [Abstract] [Full Text] [Related]

  • 59. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.
    Schiff MH, Whelton A.
    Semin Arthritis Rheum; 2000 Dec 15; 30(3):196-208. PubMed ID: 11124283
    [Abstract] [Full Text] [Related]

  • 60. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.
    Hider SL, Owen A, Hartkoorn R, Khoo S, Back D, Silman AJ, Bruce IN.
    Ann Rheum Dis; 2006 Oct 15; 65(10):1390-3. PubMed ID: 16504991
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.